CNP/cGMP signaling counteracts metabolic reprogramming in pulmonary arterial hypertension pericytes by reducing HIF1α, GLUT-1, and CAD activity, thereby normalizing glycolysis and pyrimidine synthesis and limiting hyperproliferation, highlighting its therapeutic potential. The gene discussed is HIF1A; the disease is pulmonary arterial hypertension.